Design Therapeutics (DSGN) Non-cash Items (2020 - 2025)
Design Therapeutics recorded quarterly Non-cash Items of $53.7 billion in Q4 2025, up 173.41% quarter-over-quarter from $19.6 billion in Q4 2024, and up 173.41% year-over-year from $19.6 billion in Q4 2024.
Design Therapeutics' Non-cash Items history runs 6 years deep, the most recent figure standing at $53.7 billion for Q4 2025.
- In Q4 2025, Non-cash Items rose 173.41% year-over-year to $53.7 billion; the TTM figure through Dec 2025 stood at $53.7 billion (up 173.41% YoY), while the FY2025 annual figure was $53.7 billion, up 1239866.4% from the prior year.
- Non-cash Items came in at $53.7 billion for Q4 2025 at Design Therapeutics, up from $19.6 billion in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $53.7 billion in Q4 2025 to a low of $35.3 million in Q4 2021.
- A 5-year average of $17.0 billion and a median of $10.5 billion in 2022 frame the typical range for Non-cash Items.
- Across the five-year window, Non-cash Items surged 29703.5% in 2022 and sank 89.41% in 2023, its largest moves.
- Design Therapeutics' Non-cash Items stood at $35.3 million in 2021, then soared by 29703.5% to $10.5 billion in 2022, then tumbled by 89.41% to $1.1 billion in 2023, then jumped by 1661.37% to $19.6 billion in 2024, then surged by 173.41% to $53.7 billion in 2025.
- According to Business Quant data, Non-cash Items over the past three periods registered $53.7 billion, $19.6 billion, and $1.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53.72 Bn |
| Dec 31, 2025 | 53.72 Bn |
| Dec 31, 2024 | 19.65 Bn |
| Dec 31, 2024 | 19.65 Bn |
| Dec 31, 2023 | 1.12 Bn |
| Dec 31, 2023 | 1.12 Bn |
| Dec 31, 2022 | 10.53 Bn |
| Dec 31, 2022 | 10.53 Bn |
| Dec 31, 2021 | 35.34 Mn |
| Dec 31, 2021 | 35.34 Mn |
| Dec 31, 2020 | 8.47 Mn |
| Dec 31, 2020 | 8.47 Mn |